Literature DB >> 12869214

Construction of a cytomegalovirus-based amplicon: a vector with a unique transfer capacity.

Eva Maria Borst1, Martin Messerle.   

Abstract

Cytomegalovirus (CMV) has a number of interesting properties that qualifies it as a vector for gene transfer. Especially appealing is the ability of the CMV genome to persist in hematopoietic progenitor cells and the packaging capacity of the viral capsid that accommodates a DNA genome of 230 kbp. In order to exploit the packaging capacity of the CMV capsid we investigated whether the principles of an amplicon vector can be applied to CMV. Amplicons are herpesviral vectors, which contain only the cis-active sequences required for replication and packaging of the vector genome. For construction of a CMV amplicon the sequences comprising the lytic origin of replication (orilyt) and the cleavage packaging recognition sites (pac) of human CMV were cloned onto a plasmid. A gene encoding the green fluorescent protein was used as a model transgene. The amplicon plasmid replicated in the presence of a CMV helper virus and was packaged into CMV particles, with replication and packaging being dependent on the presence of the orilyt and pac sequences. The packaged amplicon could be transferred to recipient cells and reisolated from the transduced cells. Analysis of the DNA isolated from CMV capsids revealed that the CMV amplicon was packaged as a concatemer with a size of approximately 210 kbp. The CMV amplicon vector has the potential to transfer therapeutic genes with a size of more than 200 kbp and thus provides a unique transfer capacity among viral vectors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869214     DOI: 10.1089/104303403766682223

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  7 in total

1.  Analysis of human cytomegalovirus oriLyt sequence requirements in the context of the viral genome.

Authors:  Eva-Maria Borst; Martin Messerle
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

2.  New intranasal and injectable gene therapy for healthy life extension.

Authors:  Dabbu Kumar Jaijyan; Anca Selariu; Ruth Cruz-Cosme; Mingming Tong; Shaomin Yang; Alketa Stefa; David Kekich; Junichi Sadoshima; Utz Herbig; Qiyi Tang; George Church; Elizabeth L Parrish; Hua Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-10       Impact factor: 12.779

3.  The impact of genome length on replication and genome stability of the herpesvirus guinea pig cytomegalovirus.

Authors:  Xiaohong Cui; Alistair McGregor; Mark R Schleiss; Michael A McVoy
Journal:  Virology       Date:  2009-01-26       Impact factor: 3.616

4.  Prospects for the use of artificial chromosomes and minichromosome-like episomes in gene therapy.

Authors:  Sara Pérez-Luz; Javier Díaz-Nido
Journal:  J Biomed Biotechnol       Date:  2010-08-24

5.  The essential human cytomegalovirus gene UL52 is required for cleavage-packaging of the viral genome.

Authors:  Eva Maria Borst; Karen Wagner; Anne Binz; Beate Sodeik; Martin Messerle
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

6.  Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy.

Authors:  Luka Cicin-Sain; Ivan Bubić; Margit Schnee; Zsolt Ruzsics; Christian Mohr; Stipan Jonjić; Ulrich H Koszinowski
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

7.  Human cytomegalovirus plasmid-based amplicon vector system for gene therapy.

Authors:  Kutubuddin Mahmood; Mark N Prichard; Gregory M Duke; George W Kemble; Richard R Spaete
Journal:  Genet Vaccines Ther       Date:  2005-01-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.